There is a question older than medicine, and perhaps older than philosophy, that psychiatry has largely avoided: What makes us human?
|Slideshows|November 4, 2016
Psychiatry Roundup: Tricks or Treatments?
Author(s)Laurie Martin
What do behavioral activation, video therapy, family constellation, ibogaine, and psychomagic have in common? These topics and more were chosen for this month's roundup.
Advertisement
View the information in PDF format.
Advertisement
Related to this article
APSARD is preparing US adult ADHD guidelines, delivering long-awaited screening, diagnosis, and treatment recommendations as experts discuss the upcoming release.
Review top pipeline updates from last week.
Rethink “treatment-resistant depression” by adopting difficult-to-treat depression, verifying adequate trials, and stratifying drivers like trauma and inflammation to improve outcomes.
Once-monthly subcutaneous olanzapine LAI requires no loading doses, oral supplementation, or post-injection monitoring, based on phase 3 SOLARIS data.
Neurosterix advances NTX-253, an oral M4 PAM, into phase 2 for schizophrenia after phase 1 shows promising safety and pharmacokinetics.
Andrew A. Nierenberg, MD, explains how a learning health network helps clinicians measure outcomes and redesign bipolar disorder care together with patients.
Routine symptom measures sharpen psychiatric diagnosis, speed remission, flag relapse risk, and turn EHR data into a learning system for better care.
Advertisement
Advertisement
Trending on Psychiatric Times
1
The New, Impending Adult ADHD Guidelines
2
Olanzapine LAI (Weltruza) Receives FDA Approval for Schizophrenia
3
Two New MDD Approvals: 5-HT1A Agonism and Adjunctive Atypical Antipsychotics
4
What Makes Us Human? The Role of Psychiatry and the Future DSM
5